GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » EV-to-FCF

VRCDF (Verici Dx) EV-to-FCF : -0.16 (As of Mar. 24, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Verici Dx's Enterprise Value is $0.91 Mil. Verici Dx's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was $-5.79 Mil. Therefore, Verici Dx's EV-to-FCF for today is -0.16.

The historical rank and industry rank for Verici Dx's EV-to-FCF or its related term are showing as below:

VRCDF' s EV-to-FCF Range Over the Past 10 Years
Min: -3   Med: -1.68   Max: -0.29
Current: -0.29

During the past 4 years, the highest EV-to-FCF of Verici Dx was -0.29. The lowest was -3.00. And the median was -1.68.

VRCDF's EV-to-FCF is ranked worse than
100% of 103 companies
in the Medical Diagnostics & Research industry
Industry Median: 27.22 vs VRCDF: -0.29

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-24), Verici Dx's stock price is $0.03. Verici Dx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.026. Therefore, Verici Dx's PE Ratio (TTM) for today is At Loss.


Verici Dx EV-to-FCF Historical Data

The historical data trend for Verici Dx's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx EV-to-FCF Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- -12.27 -1.48 -2.56

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-FCF Get a 7-Day Free Trial - -1.48 - -2.56 -

Competitive Comparison of Verici Dx's EV-to-FCF

For the Diagnostics & Research subindustry, Verici Dx's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verici Dx's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Verici Dx's EV-to-FCF falls into.



Verici Dx EV-to-FCF Calculation

Verici Dx's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=0.912/-5.791
=-0.16

Verici Dx's current Enterprise Value is $0.91 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Verici Dx's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was $-5.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verici Dx  (OTCPK:VRCDF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Verici Dx's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.03/-0.026
=At Loss

Verici Dx's share price for today is $0.03.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Verici Dx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.026.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Verici Dx EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Verici Dx's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines